CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to PHM.MC

Eslicarbazepine acetate

Phase 3
PharmaMar, S.A. (PHM.MC)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

2

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Epilepsy

Clinical Trial

NCT00910247

Last updated: 6/28/2026

Patent & Exclusivity
ActiveRLD

Latest Patent Expiry

Aug 24, 2032(5y 11m)

Patents Listed

7

Application

NDA 022416
Regulatory Approvals
EMA4/21/2009

Zebinix

Zebinix is indicated as adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation.

View on EMA
EMA4/21/2009

Exalief

Exalief is indicated as adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation.

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.